Has Elizabeth Boots received payments from drug or device companies?

Yes. Drug and device makers reported $567 in general payments to Elizabeth Boots across 34 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Elizabeth Boots did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Elizabeth Boots come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Elizabeth Boots

Psychiatric/Mental Health · Williston, NDNPI 1114381845

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.6% of the total across 34 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Alkermes, Inc. at 42.0% of the total. Reporting peaked in 2022 at $223 and has fallen 86.3% since, to $31 in 2025.

$567in general payments, 2019–2025

Across 34 payments — averaging $16.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Alkermes, Inc.$238
AbbVie$123
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$48
Takeda Pharmaceuticals U.S.A., Inc.$35
Otsuka America Pharmaceutical, Inc.$33
E.r. Squibb & Sons, L.L.C.$31
plus $60 from 3 others

What the payments were for

Food & beverage$53695%
Education$315%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Alkermes, Inc.	14	$238
AbbVie	8	$123
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	3	$48
Takeda Pharmaceuticals U.S.A., Inc.	2	$35
Otsuka America Pharmaceutical, Inc.	2	$33
E.r. Squibb & Sons, L.L.C.	1	$31
Sunovion Pharmaceuticals Inc.	2	$21
Teva Pharmaceuticals USA, Inc.	1	$21
Neurocrine Biosciences, Inc.	1	$18

How this compares

$567 in reported general payments places this provider in the 70th percentile of 92 psychiatric/mental health providers in North Dakota.

See all psychiatric/mental health providers in North Dakota →

Medicare billing

Part B allowed, 2024

$10,330

Medicare patients

Services billed

115

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
IngrezzaValbenazine Tosylate	34	$285,902
VraylarCariprazine Hcl	54	$75,921
VivitrolNaltrexone Microspheres	15	$24,155
CaplytaLumateperone Tosylate	12	$19,103
Clozapine	58	$12,962
Topiramate	12	$4,005
Escitalopram Oxalate	51	$2,265
Doxepin Hcl	12	$1,733
Venlafaxine Hcl ErVenlafaxine Hcl	19	$1,503
Vilazodone Hcl	12	$1,139
Desvenlafaxine Succinate ErDesvenlafaxine Succinate	25	$583
Olanzapine	34	$513
Divalproex Sodium ErDivalproex Sodium	44	$446
Buspirone Hcl	11	$276
Hydroxyzine Pamoate	18	$244

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza	$18	$285,90234 claims
AbbVieVraylar	$123	$75,92154 claims
Alkermes, Inc.Vivitrol	$238	$24,15515 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta	$48	$19,10312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 92 psychiatric/mental health providers in North Dakota.

Other psychiatric/mental health in Williston

Brittany BollingerWilliston$933
McKenzie MoorWilliston$903
Charlotte FerrellWilliston$503
Jessica Graham SteinhauerFargo$8K
Madison KirschBismarck$3K
Roxann BrownMinot$3K
Rebecca KussJamestown$3K
Tonya AndersonMinot$3K
Jennifer WoiwodeMinot$2K
Linda VolnessFargo$2K

See the full list for North Dakota →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →